PharmaEssentia Corp. submitted the IND application of phase I clinical trial of P2203 to Taiwan Food and Drug Administration (TFDA). Neutrophil is a type of white blood cell, and G-CSF agents have been the standard of care for neutropenia, a condition where patients have a low number of neutrophils in their blood.

G-CSF agents can shorten the period of neutropenia and reduce the risk of infection. Estimated date of completion is Subject recruitment is expected to be completed in 2025. The timeline will be adjusted according to the actual progress of the clinical trial, and disclosure will be made upon the progress of the study according to the regulations.